Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

60%

3 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
3(75.0%)
Phase 1
1(25.0%)
4Total
Phase 3(3)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT00670332Terminated

Prognostic Assessment of Contrast Echocardiography (PACE Study)

Role: lead

NCT00669851Phase 3Completed

Acquiring Consensus for Contrast Echocardiography System Settings - ACCESS Study

Role: lead

NCT00156780Phase 1Completed

Phase 1 Safety and Pharmacokinetic Study of AI-700 in Patients With Diminished DLCO and COPD and/or CHF

Role: lead

NCT00156793Phase 3Completed

Phase 3 Imaging and Safety Study of AI-700 in Patients With Suspected Coronary Artery Disease Undergoing SPECT Imaging

Role: lead

NCT00156845Phase 3Completed

Phase 3 Safety and Imaging Study of AI-700 in Patients With Suspected Coronary Artery Disease Undergoing Coronary Angiography

Role: lead

All 5 trials loaded